Company intelligence / Profile preview

OpalGenix

Indianapolis, Indiana, United Statesopalgenix.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

OpalGenix has developed GPS-Opioid™, a pharmacogenetic-based decision support tool to personalize opioid selection and dosing. The company has completed pediatric clinical studies, is running adult trials, holds >10 US/EU patents, and received NIH STTR grant funding. Their technology demonstrates >80% sensitivity/specificity in predicting opioid risks.

Therapeutic areas: OtherNeurology
Modalities: Device (laboratory-developed test)Diagnostic technology (pharmacogenetic panel)
Industry: Molecular Diagnostics

Partnerships

NIH STTR grant recipient; no major pharma partnerships disclosed as of June 2025

Beyond the preview

Go deeper on OpalGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OpalGenix.

Explore the full profile